Eurosurv. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso prov

[tetano]

• Massimo Fabiani[SUP]1[/SUP] , Mauro Ramigni[SUP]2[/SUP] , Valentina Gobbetto[SUP]2[/SUP] , Alberto Mateo-Urdiales[SUP]1,3[/SUP] , Patrizio Pezzotti[SUP]1[/SUP] , Cinzia Piovesan[SUP]2 [/SUP]

Data on effectiveness of the BioNTech?/Pfizer COVID-19 vaccine in real-world settings are limited. In a study of 6,423 healthcare workers in Treviso Province, Italy, we estimated that, within the time intervals of 14?21 days from the first and?at least?7 days from the second dose, vaccine effectiveness in preventing SARS-CoV-2 infection was 84% (95% confidence interval (CI): 40?96) and 95% (95% CI: 62?99), respectively. These results could support the ongoing vaccination campaigns by providing evidence for targeted communication.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.17.2100420#html_fulltext